8-K: Repare Therapeutics Acquired by XenoTherapeutics for $2.20/Share

Repare Therapeutics Inc. announced the completion of its acquisition by XenoTherapeutics, Inc., with shareholders receiving cash and contingent value rights.

Summary

• Repare Therapeutics Inc. has completed its acquisition by XenoTherapeutics, Inc. and its wholly-owned subsidiary, Xeno Acquisition Corp., through a statutory plan of arrangement.
• Shareholders received a cash payment of approximately US$2.20 per common share, determined by the company's cash balance prior to closing, after deducting certain transaction costs, outstanding liabilities, and a transaction fee to Xeno.
• Each shareholder also received one non-transferable contingent value right (CVR) for each common share, representing the right to a pro rata portion of potential future cash payments.
• The Arrangement was approved by Repare's shareholders on January 16, 2026, and a final order was issued by the Superior Court of Quebec on January 23, 2026.
• As a result of the acquisition, Repare's common shares are expected to cease trading on the Nasdaq Global Select Market on or about January 28, 2026, and the company will be delisted and deregistered.
• Repare has applied to cease being a reporting issuer in Quebec, and the company is now a wholly-owned subsidiary of Xeno Acquisition Corp.

Sentiment

Score: 6

Explanation: The completion of the acquisition provides a definitive cash payout and potential future value through CVRs for shareholders, which is a clear resolution. However, it also signifies the end of Repare Therapeutics as a publicly traded entity, removing it from public investment opportunities. The outcome was expected given prior announcements and approvals.

Positives

• Shareholders received a definitive cash payment of approximately US$2.20 per common share, providing a clear liquidity event.
• Shareholders also received contingent value rights (CVRs), offering potential future cash payments based on certain conditions.
• The acquisition provides a clear exit strategy for Repare Therapeutics' public shareholders.

Negatives

• Repare Therapeutics Inc. will cease to be a publicly traded company, leading to the delisting of its common shares from Nasdaq.
• Existing shareholders will no longer hold equity in Repare Therapeutics Inc. as it becomes a private entity.
• The company will deregister its shares and suspend reporting obligations, significantly reducing transparency for former public investors.

Risks

• The possibility that common shares may not be delisted from the Nasdaq Global Select Market within the currently contemplated timing or at all, due to failure to satisfy necessary conditions.
• The company's application to cease to be a reporting issuer under applicable Quebec securities laws may not be accepted or may be delayed.
• General risks and uncertainties described in the Proxy Statement and other SEC and AMF filings.

Future Outlook

The company expects its common shares to cease trading on the Nasdaq Global Select Market on or about January 28, 2026, followed by delisting and deregistration under the U.S. Securities Exchange Act of 1934. Repare has also applied to cease being a reporting issuer in Quebec.

Management Comments

• Repare Therapeutics Inc. announced the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company by XenoTherapeutics, Inc. and Xeno Acquisition Corp.

Industry Context

This acquisition represents a consolidation event in the biotechnology sector, specifically involving a clinical-stage precision oncology company. For XenoTherapeutics, a non-profit focused on xenotransplantation, acquiring Repare, which specializes in synthetic lethality and DNA damage repair for cancer, suggests a potential strategic expansion into new therapeutic areas or an acquisition of valuable assets/IP. The delisting of Repare removes a player from the public oncology investment landscape.

Comparison to Industry Standards

• NA. This filing details the completion of an acquisition and subsequent delisting, rather than operational or financial performance that can be benchmarked against industry peers or global standards.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received a cash payment of approximately US$2.20 per share and CVRs, providing a liquidity event and potential future upside, but losing equity in the company.
• Employees: Not explicitly mentioned, but a change in control and management often leads to organizational restructuring.
• Customers/Suppliers: No direct impact mentioned, but the change in ownership could influence future business relationships or strategic direction.
• Creditors: Outstanding liabilities were deducted from the cash balance to determine the per-share payout, implying these were addressed as part of the transaction.

Next Steps

• Nasdaq to suspend trading of Repare's common shares effective after the closing of trading on January 28, 2026.
• Nasdaq to file a Form 25 with the SEC to effect the delisting and deregistration of Repare's shares.
• Xeno Acquisition Corp. intends to file a Form 15 with the SEC to terminate registration and suspend reporting obligations under the Exchange Act.
• Repare's application to cease being a reporting issuer in Quebec is pending.
• Consideration for the common shares will be remitted to Broadridge Corporate Issuer Solutions, LLC and paid to former shareholders as soon as reasonably practicable.

Key Dates

Recommendation

The company has been acquired, and its shares are being delisted from Nasdaq. Existing shareholders have received a cash payment and contingent value rights (CVRs) in exchange for their shares. There is no longer a public market for Repare Therapeutics' common shares, and thus no opportunity for new investment. For any remaining shareholders, the recommendation is to complete the process of tendering shares to receive the cash and CVRs, as the company is no longer a publicly tradable entity.

Keywords

Repare Therapeutics, XenoTherapeutics, Acquisition, Merger, Biotechnology, Oncology, Synthetic Lethality, Delisting, CVR, Contingent Value Right, Nasdaq, SEC Filing, Corporate Governance, RP-3467, RP-1664, Xenotransplantation